Aurobindo Pharma has received final USFDA approval to launch generic Rivaroxaban 2.5mg tablets in the US, targeting a $447 ...

Denosumab works by specifically targeting the RANK ligand (RANKL), a critical protein in the lifecycle of osteoclasts, the ...

Sun Pharma declined 0.93 per cent to Rs 1,689.35. About10 per cent of the Sun Pharma's US specialty revenues is formulated in ...

Aurobindo Pharma jumped 3.42% to Rs 1,119.55 after the pharma company said that it has received final approval from US Food and Drug Administration (USFDA) to manufacture and market Rivaroxaban ...

Generic Xarelto is a blood thinner medicine that lowers blood clotting. Aurobindo has obtained the Food and Drug ...

Aurobindo's manufacturing operations have once again landed the Indian drugmaker in hot water with the U.S. FDA. | ...

Generic drugmaker Aurobindo Pharma has received final approval from the U.S. Food and Drug Administration (U.S. FDA) to manufacture and market Rivaroxaban Tablets USP, 2.5 mg. The approved ...

The Nifty Pharma index closed 1.21 per cent up at 21126.75. Benchmark NSE Nifty50 index ended up 414.46 points at 23851.65, ...

Aurobindo Pharma has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Rivaroxaban Tablets USP, 2.5mg, the generic equivalent of Janssen ...

Aurobindo Pharma announced that its subsidiary CuraTeQ Biologics has received successful trial results for its new bone treatment medicine. The drug, called BP16, is a biosimilar of an existing ...

An inhalers and derma products manufacturing plant of Aurobindo Pharma subsidiary Aurolife Pharma LLC in the U.S. has been issued 11 observations by the United States Food and Drug Administration.

Companies like Dr Reddy’s Laboratories, Cipla, Sun Pharmaceutical Industries, and Aurobindo Pharma could see pressure on their margins if tariffs are imposed.